Status: Recruiting
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma. The name of the study drugs involved in this study are: * Naxitamab (A type of monoclonal antibody) * Irinotecan (A standard of care chemotherapy) * Temozolomide (A standard of care chemotherapy) * Sargramostim (A standard of care, granulocyte-macrophage colony stimulating factor)
Participants needed: 18
Trial details
Phase: Phase 1Age: 1-30Biological sex: AllType: InterventionalSponsor: Steven DuBois, MDUpdated: Jul 14, 2025Locations: 2
Eligibility criteria
Histologic Diagnosis: Patients must have had histologic verification of neurobla... [+42]
Chronic (more than 2 weeks duration) diarrhea > grade 1 [+15]